Results 191 to 200 of about 37,394 (238)

Modified High-Dose Melphalan and Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis. [PDF]

Biol Blood Marrow Transplant, 2018
Nguyen VP, Landau H, Quillen K, Brauneis D, Shelton AC, Mendelson L, Rahman H, Sloan JM, Sarosiek S, Sanchorawala V.   +9 more
europepmc   +1 more source

Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation. [PDF]

Haematologica, 2018
Sidiqi MH, Aljama MA, Jevremovic D, Morice WG, Timm M, Buadi FK, Warsame R, Lacy MQ, Dispenzieri A, Dingli D, Gonsalves WI, Kumar S, Kapoor P, Kourelis T, Leung N, Hogan WJ, Gertz M.   +16 more
europepmc   +1 more source

[Immunoglobulin light-chain type amyloidosis].

Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1995
openaire   +1 more source

Sequential cryoglobulinemia-associated glomerulonephritis and light-chain amyloidosis in monoclonal gammopathy of renal significance. [PDF]

CEN Case Rep
Nakayama Y, Harada M, Hashimoto K, Ehara T, Kamijo Y.   +4 more
europepmc   +1 more source

Systemic immunoglobulin light chain amyloidosis [PDF]

Nature Reviews Disease Primers, 2018
Systemic immunoglobulin light chain amyloidosis is a protein misfolding disease caused by the conversion of immunoglobulin light chains from their soluble functional states into highly organized amyloid fibrillar aggregates that lead to organ dysfunction.
G. Merlini, A. Dispenzieri, V. Sanchorawala, S. Schönland, G. Palladini, P. Hawkins, M. Gertz   +6 more
semanticscholar   +7 more sources

Some of the next articles are maybe not open access.

Related searches:

Systemic Immunoglobulin Light Chain Amyloidosis–Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome

Mayo Clinic Proceedings, 2016
OBJECTIVE To characterize the natural history of immunoglobulin light chain amyloidosis-associated myopathy and to provide guidelines for recognition.
Eli Muchtar, Daniele Derudas, Michelle L Mauermann   +2 more
exaly   +2 more sources

Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment

American journal of hematology/oncology, 2023
Immunoglobulin light chain amyloidosis is a clonal, nonproliferative plasma cell disorder in which fragments of immunoglobulin light or heavy chain are deposited in tissues.
M. Gertz
semanticscholar   +1 more source

Immunoglobulin light chain amyloidosis

Expert Review of Hematology, 2013
Primary light chain amyloidosis is the most common form of systemic amyloidosis and is caused by misfolded light chains that cause proteotoxicity and rapid decline of vital organ function. Early diagnosis is essential in order to deliver effective therapy and prevent irreversible organ damage.
MERLINI, GIAMPAOLO, Comenzo RL, Seldin DC, Wechalekar A, Gertz MA   +4 more
openaire   +3 more sources

Treatment of immunoglobulin light chain amyloidosis

Current Hematologic Malignancy Reports, 2009
No therapy is uniformly effective in the management of immunoglobulin light chain amyloidosis (AL amyloidosis). Despite the common generalization, therapy is highly effective. Options available to patients with AL amyloidosis include high-dose therapy, but this is applicable to only about one fourth of patients.
Morie A, Gertz, Steven R, Zeldenrust
openaire   +2 more sources